FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation

Table 2 Clinical and biochemical features of healthy control subjects and patients with nonalcoholic steatohepatitis

	Healthy control(n = 4)	NASH(n = 18)	P value
Female (n)	2	7	NS
Age (yr)	47.20 ± 6.04	51.29 ± 12.33	NS
ALT (U/L)	32.40 ± 17.09	128.27 ± 98.07	< 0.05
AST (U/L)	16.80 ± 4.92	71.71 ± 53.47	< 0.05
Alkaline phosphatase (U/L)	96.20 ± 17.83	101.74 ± 24.09	NS
Gamma-glutamyl transferase (U/L)	14.00 ± 15.68	95.40 ± 56.94	< 0.05
BMI (kg/m2)	19.78 ± 1.19	26.63 ± 1.55	< 0.05
Fasting insulin (uIU/mL)	7.75 ± 4.15	14.05 ± 2.94	< 0.05
Triglycerides (mmol/L)	1.59 ± 0.10	2.85 ± 0.92	< 0.05

All values are means ± SD. NASH: Nonalcoholic steatohepatitis; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NS: Not significant.